Matches in Wikidata for { <http://www.wikidata.org/entity/Q104752190> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- Q104752190 description "article scientifique publié en 2021" @default.
- Q104752190 description "artikulo sientifíko" @default.
- Q104752190 description "artículu científicu espublizáu en marzu de 2021" @default.
- Q104752190 description "scientific article published on 01 March 2021" @default.
- Q104752190 description "wetenschappelijk artikel" @default.
- Q104752190 description "наукова стаття, опублікована в березні 2021" @default.
- Q104752190 description "գիտական հոդված հրատարակված 2021 թվականի մարտի 1-ին" @default.
- Q104752190 name "Molybdenum Dioxide (MoS₂)/Gadolinium (Gd) Containing Arginine-Glycine-Aspartic Acid (RGD) Sequences as New Nano-Contrast Agent for Cancer Magnetic Resonance Imaging (MRI)" @default.
- Q104752190 name "Molybdenum Dioxide (MoS₂)/Gadolinium (Gd) Containing Arginine-Glycine-Aspartic Acid (RGD) Sequences as New Nano-Contrast Agent for Cancer Magnetic Resonance Imaging (MRI)" @default.
- Q104752190 type Item @default.
- Q104752190 label "Molybdenum Dioxide (MoS₂)/Gadolinium (Gd) Containing Arginine-Glycine-Aspartic Acid (RGD) Sequences as New Nano-Contrast Agent for Cancer Magnetic Resonance Imaging (MRI)" @default.
- Q104752190 label "Molybdenum Dioxide (MoS₂)/Gadolinium (Gd) Containing Arginine-Glycine-Aspartic Acid (RGD) Sequences as New Nano-Contrast Agent for Cancer Magnetic Resonance Imaging (MRI)" @default.
- Q104752190 prefLabel "Molybdenum Dioxide (MoS₂)/Gadolinium (Gd) Containing Arginine-Glycine-Aspartic Acid (RGD) Sequences as New Nano-Contrast Agent for Cancer Magnetic Resonance Imaging (MRI)" @default.
- Q104752190 prefLabel "Molybdenum Dioxide (MoS₂)/Gadolinium (Gd) Containing Arginine-Glycine-Aspartic Acid (RGD) Sequences as New Nano-Contrast Agent for Cancer Magnetic Resonance Imaging (MRI)" @default.
- Q104752190 P1433 Q104752190-C05D6AF5-4BE5-45D2-A743-62E2FFAFAC3D @default.
- Q104752190 P1476 Q104752190-F2017C63-0943-4DAB-9BB3-0CCE13D72D9F @default.
- Q104752190 P2093 Q104752190-8526FC82-F797-43F5-A296-CBA300425B3B @default.
- Q104752190 P2093 Q104752190-E4F0F025-BC55-41CC-BCD7-BA3A81885BBD @default.
- Q104752190 P304 Q104752190-ED21454B-51EC-4098-90E7-0D068BEC9A5E @default.
- Q104752190 P31 Q104752190-84BE8A7F-B062-444D-AFE9-C6E4C1CE6F85 @default.
- Q104752190 P356 Q104752190-1ADB9E48-F939-44EB-A46B-2E438515312C @default.
- Q104752190 P433 Q104752190-6ECB4984-C258-4817-B211-0CCC48C92D1B @default.
- Q104752190 P478 Q104752190-5DF712C0-C3E0-47FE-B940-DDAE4D7CFF47 @default.
- Q104752190 P577 Q104752190-86438771-6265-4C73-9234-E0053853252D @default.
- Q104752190 P698 Q104752190-8B0D96BF-3C30-4FAA-B8B0-8603844A9E06 @default.
- Q104752190 P356 JNN.2021.18894 @default.
- Q104752190 P698 33404402 @default.
- Q104752190 P1433 Q2364336 @default.
- Q104752190 P1476 "Molybdenum Dioxide (MoS₂)/Gadolinium (Gd) Containing Arginine-Glycine-Aspartic Acid (RGD) Sequences as New Nano-Contrast Agent for Cancer Magnetic Resonance Imaging (MRI)" @default.
- Q104752190 P2093 "Weijing Li" @default.
- Q104752190 P2093 "Xiaoguang Hao" @default.
- Q104752190 P304 "1403-1412" @default.
- Q104752190 P31 Q13442814 @default.
- Q104752190 P356 "10.1166/JNN.2021.18894" @default.
- Q104752190 P433 "3" @default.
- Q104752190 P478 "21" @default.
- Q104752190 P577 "2021-03-01T00:00:00Z" @default.
- Q104752190 P698 "33404402" @default.